ASCO GI 2023 Conference Coverage

 

Videos
07:46

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase II Clinical Trial to Study the Use of Cabozantinib in Patients With HCC Post IO Treatment

FEATURING Stephen L. Chan
  • 506 views
  • March 22, 2023
12:04

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Preliminary Efficacy and Correlative Results of the Phase II Trial HCRN GI16-288: Perioperative CV301 Vaccination in Combination With Nivo and Systemic Chemo for Resectable Hepatic-Limited mCRC

FEATURING Kristen Spencer
  • 96 views
  • February 23, 2023
06:17

ASCO GI 2023 Conference Coverage

ASCO GI 2023 INTEGRATE IIa Randomised, Double-Blind, Phase III Study: Regorafenib vs. Placebo in Refractory Advanced Gastro-Esophageal Cancer

FEATURING Nick Pavlakis
  • 147 views
  • February 23, 2023
06:25

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Overall Survival in Gastrointestinal Neuroendocrine Tumors Based on Primary Site, Stage, and Surgery

FEATURING Bahar Laderian
  • 164 views
  • February 23, 2023
  • 1
05:13

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Primary Endpoint Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study: Nanvuranlat, LAT1 Inhibitor for Patients With Pretreated Advanced Refractory BTC

FEATURING Junji Furuse
  • 56 views
  • February 23, 2023
13:21

ASCO GI 2023 Conference Coverage

ASCO GI 2023 TIMES Trial: Advancing Precision Immunotherapy for Gastric Cancer Through TME Assessment

FEATURING Dongqiang Zeng
  • 150 views
  • February 23, 2023
09:24

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Randomized Phase II VELO Clinical Trial: Panitumumab + Trifluridine/Tipiracil as Anti-EGFR Rechallenge Therapy in Chemo-Refractory RAS WT mCRC

FEATURING Stefania Napolitano
  • 146 views
  • February 16, 2023
11:02

ASCO GI 2023 Conference Coverage

ASCO GI 2023 3-Year Follow-Up From CheckMate 649: Nivo + Chemo vs. Chemo as 1L Treatment for Advanced GC/GEJC/EAC

FEATURING Yelena Y. Janjigian
  • 598 views
  • February 10, 2023
  • 5
30:57

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Final Surgical Salvage Results From OPERA Phase 3 Randomised Trial: Do Nonoperative Modality Treatments of Rectal Cancer Compromise the Chance of Cure?

FEATURING Arthur Sun Myint
  • 221 views
  • February 10, 2023
  • 1
08:54

ASCO GI 2023 Conference Coverage

ASCO GI 2023 CRC Highlights: Phase 3 SUNLIGHT & PARADIGM Trials

FEATURING Alan Venook
  • 512 views
  • February 10, 2023
  • 1
09:02

ASCO GI 2023 Conference Coverage

ASCO GI 2023: A Study of Pembro in Combination With Y90 Radioembolization in Patients With Poor Prognosis HCC

FEATURING Ashwin Somasundaram
  • 161 views
  • February 9, 2023
  • 1
05:56

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase II IMMULAB Trial: IO With Pembro in Combination With Local Ablation for Patients With Early Stage HCC

FEATURING Arndt Vogel
  • 101 views
  • February 7, 2023
  • 2
05:26

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Results From the TAPUR Study: Pertuzumab + Trastuzumab for Biliary Tract Cancer With ERBB2/3 Amplification, Overexpression, or Mutation

FEATURING Timothy Cannon
  • 166 views
  • February 7, 2023
10:19

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Promoting Multidisciplinary Care for Patients With Unresectable HCC: Findings From a Quality Improvement Initiative Across Two Community Cancer Centers

FEATURING Ari Baron
  • 55 views
  • February 7, 2023
  • 1
07:46

ASCO GI 2023 Conference Coverage

FGFR2-Amplified Gastroesophageal Adenocarcinoma Is a Distinct Genomic Class: Lessons Learned From a Liquid Biopsy Platform

FEATURING Bushra Shariff
  • 61 views
  • February 7, 2023
  • 1
06:59

ASCO GI 2023 Conference Coverage

ASCO GI 2023 CCTG HE.1 - Phase 3 Study: Palliative RT for Symptomatic HCC and Liver Metastases

FEATURING Laura Dawson
  • 80 views
  • February 6, 2023
09:43

ASCO GI 2023 Conference Coverage

ASCO GI 2023 NRG/RTOG 1112 Randomized Phase 3 Study: Sorafenib vs. SBRT Followed by Sorafenib in Advanced HCC

FEATURING Laura Dawson
  • 442 views
  • February 6, 2023
  • 8
05:32

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Continuous Maintenance Capecitabine Dosing for Advanced CRC and Pancreatic Cancers: Single-Institution, Retrospective, Real-World Study

FEATURING Reetu Mukherji
  • 128 views
  • February 6, 2023
  • 2
20:09

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Debate: For a Fit Patient With Unresectable Metastatic RAS Wild-Type Sigmoid Colon Adenocarcinoma, 1L EGFR Antibody Is an Essential Treatment - PRO

FEATURING Kai-Keen Shiu
  • 149 views
  • February 6, 2023
  • 1
04:06

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase Ib OBERTO-201 Study: Evaluating Safety, Tolerability, Immunogenicity, & Efficacy of Multiple Subcutaneous Injections of PolyPEPI1018 Vaccine as an Add-On IO to TAS-102 in Late-Stage MSS mCRC

FEATURING Joleen Hubbard
  • 43 views
  • February 3, 2023
06:08

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Survival Outcomes and Functional Results of VOLTAGE-A: Preoperative CRT and Consolidation Nivo in Patients With Both MSS and MSI-H Locally Advanced Rectal Cancer (EPOC 1504)

FEATURING Yuichiro Tsukada
  • 78 views
  • February 3, 2023
  • 1
23:58

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Key Studies

FEATURING Richard Kim, Rutika Mehta
  • 3,099 views
  • February 3, 2023
  • 17
10:41

ASCO GI 2023 Conference Coverage

ASCO GI 2023 NAPOLI-3 Randomized, Open-Label Phase 3 Study: Liposomal Irinotecan + 5-Fluorouracil/Leucovorin + Oxaliplatin (NALIRIFOX) vs. nab-Paclitaxel + Gemcitabine in Treatment-Naïve Patients With mPDAC

FEATURING Zev A. Wainberg
  • 398 views
  • February 1, 2023
  • 4
07:49

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Preliminary Clinical Results of the NERDY Study: Immunotherapy in RAS Mutant mCRC - Could CTLA-4 Blockade Increase the Efficacy of Anti PD-1 Agents?

FEATURING Alessandra Anna Prete
  • 74 views
  • February 1, 2023
  • 1
05:32

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase 3 Randomized SWOG 1815 Trial: Gemcitabine, Cisplatin, & nab-Paclitaxel vs. Gemcitabine & Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

FEATURING Rachna Shroff
  • 255 views
  • February 1, 2023
  • 4
05:29

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase 3 BREAKWATER Study Safety Lead-In: Encorafenib + Cetuximab + Chemo for BRAFV600E mCRC

FEATURING Scott Kopetz
  • 663 views
  • February 1, 2023
  • 3
16:19

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Exploring Immunotherapy Combinations for DDR-Deficient Pancreatic Cancer

FEATURING Kim Reiss Binder
  • 134 views
  • February 1, 2023
  • 2
08:15

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Zanidatamab + Chemo as 1L Treatment for HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

FEATURING Elena Elimova
  • 126 views
  • January 31, 2023
  • 1
04:20

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Final Results of the Phase II RE-ExPEL Study: Ramucirumab Beyond Progression + TAS 102 in Advanced/Metastatic Adenocarcinoma of the Stomach or GEJ, After Treatment Failure on a Ramucirumab-Based Therapy

FEATURING Thorsten Oliver Götze
  • 171 views
  • January 31, 2023
  • 1
12:31

ASCO GI 2023 Conference Coverage

ASCO GI 2023 29-Month Follow-Up From CheckMate 648: Nivo + Chemo or Ipi vs. Chemo as 1L Treatment for Advanced Esophageal Squamous Cell Carcinoma

FEATURING Ken Kato
  • 108 views
  • January 31, 2023
  • 1
07:20

ASCO GI 2023 Conference Coverage

ASCO GI 2023 ctDNA Informs Clinical Practice in Patients With Recurrent/Metastatic Gastroesophageal Cancers

FEATURING Rutika Mehta
  • 505 views
  • January 31, 2023
  • 3
06:52

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Multicenter, Single-Arm, Multi-Cohort, Phase II INFINITY Trial: Tremelimumab & Durvalumab as Neoadjuvant Treatment of Patients With MSI-H Resectable GC/GEJC

FEATURING Filippo Pietrantonio
  • 222 views
  • January 31, 2023
  • 1
11:46

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Debate: For a Fit Patient With Unresectable Metastatic RAS WT Sigmoid Colon Adenocarcinoma, 1L EGFR Antibody Is an Essential Treatment - CON

FEATURING Ardaman Shergill
  • 199 views
  • January 31, 2023
09:47

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Neoadjuvant Immunotherapy in Localized dMMR CRC

FEATURING Sakti Chakrabarti
  • 179 views
  • January 31, 2023
  • 1
09:12

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Comparative Analysis of the Molecular Profile and Tumor Immune Microenvironment of HER2 Low vs. High Expressing Gastroesophageal Cancers

FEATURING Ali Alqahtani
  • 203 views
  • January 28, 2023
  • 4
04:46

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Confidence Study: Effectiveness & Safety of Encorafenib-Cetuximab in BRAFV600E mCRC

FEATURING Ana Fernandez Montes
  • 94 views
  • January 28, 2023
07:58

ASCO GI 2023 Conference Coverage

ASCO GI 2023 ctDNA Dynamics and Clinical Outcome in mCRC Patients Undergoing Frontline Chemo

FEATURING Michele Ghidini
  • 103 views
  • January 28, 2023
09:41

ASCO GI 2023 Conference Coverage

ASCO GI 2023 New Prognostic Index of Advanced Gastric Cancer Using the Data From JCOG1013

FEATURING Daisuke Takahari
  • 126 views
  • January 28, 2023
  • 1
04:41

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Characterization of Long-Term Survivors in the TOPAZ-1 Study: Durvalumab or Placebo + Gemcitabine & Cisplatin in Advanced Biliary Tract Cancer

FEATURING Mohamed Bouattour
  • 304 views
  • January 28, 2023
  • 2
12:06

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Surgical Viewpoint on Non-Operative Management of Rectal Cancer: When to Bring Out the Scalpel

FEATURING Tsuyoshi Konishi
  • 80 views
  • January 28, 2023
  • 1
27:37

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

FEATURING Nataliya Uboha, Anita Turk, Kristen Spencer, Michael Cecchini
  • 4,108 views
  • January 26, 2023
  • 19
05:34

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Biomarker Study of The Phase III PARADIGM Trial: Negative Hyperselection of Patients With RAS WT mCRC for Panitumumab

FEATURING Kohei Shitara
  • 325 views
  • January 26, 2023
  • 2
07:51

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase 3 SPOTLIGHT Study Primary Results: Zolbetuximab + mFOLFOX6 as 1L Treatment for Patients With CLDN18.2+/HER2- Locally Advanced Unresectable/Metastatic Gastric or GEJ Adenocarcinoma

FEATURING Kohei Shitara
  • 489 views
  • January 26, 2023
  • 6
07:40

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Kinetics of Postoperative Circulating cfDNA and Impact on MRD Detection Rates in Patients With Resected Stage I-III CRC

FEATURING Stacey Cohen
  • 69 views
  • January 26, 2023
06:32

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Analysis of HLA Gene Expression in Patients With dMMR/MSI-H CRC Resistant to Immune Checkpoint Inhibitors

FEATURING Heinz-Josef Lenz
  • 105 views
  • January 26, 2023
  • 1
07:43

ASCO GI 2023 Conference Coverage

ASCO GI 2023 ctDNA for Response Assessment in Patients With Anal Cancer Treated With Definitive CRT

FEATURING Janet Alvarez
  • 130 views
  • January 26, 2023
06:55

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Evaluation of Clinical Benefit and PFS Ratio of Targeted Treatments in a Prospective Cohort Study of Patients With Biliary Tract Cancers

FEATURING Monica Niger
  • 90 views
  • January 26, 2023
  • 2
05:19

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase 3 STELLAR-303 Study: XL092 in Combination With Atezolizumab vs. Regorafenib in Patients With Previously Treated mCRC

FEATURING J. Randolph Hecht
  • 391 views
  • January 25, 2023
  • 2
10:26

ASCO GI 2023 Conference Coverage

Phase 3 Randomized SUNLIGHT Study: Trifluridine/Tipiracil + Bevacizumab for 3L Treatment of Refractory mCRC

FEATURING Josep Tabernero
  • 533 views
  • January 25, 2023
06:16

ASCO GI 2023 Conference Coverage

ASCO GI 2023 on Organ Preservation and Total Neoadjuvant Therapy for Rectal Cancer: Investigating Long-Course CRT vs. Short-Course Radiation Therapy

FEATURING Paul Romesser
  • 360 views
  • January 25, 2023
06:55

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Results From a Phase 1a/1b Study: Botensilimab, a Novel Innate/Adaptive Immune Activator, + Balstilimab in Metastatic Heavily Pretreated Microsatellite Stable CRC

FEATURING Anthony El-Khoueiry
  • 157 views
  • January 25, 2023
10:41

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase 2, Randomized, Double-Blind, Placebo-Controlled IMbrave151 Study: Bev + Atezo & Gem/Cis in Advanced Biliary Tract Cancer

FEATURING Anthony El-Khoueiry
  • 202 views
  • January 25, 2023
  • 1
08:47

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Use of ctDNA for Early Assessment of Treatment Response in Advanced CRC: A Real-World Analysis

FEATURING Pashtoon Kasi
  • 120 views
  • January 24, 2023
  • 1
13:36

ASCO GI 2023 Conference Coverage

ASCO GI 2023 CTCs as Liquid Biopsies in Patients With mCRC vs. Other GI Malignancies

FEATURING Pashtoon Kasi
  • 149 views
  • January 24, 2023
  • 4
06:32

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Randomized Phase III FIRE-4 study (AIO KRK-0114): Investigating a Switch Maintenance Concept With 5-FU + Bev After FOLFIRI + Cet Induction Treatment vs. Continued Treatment With FOLFIRI + Cet in RAS-wt mCRC

FEATURING Sebastian Stintzing
  • 361 views
  • January 23, 2023
  • 2
06:28

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Survival Analysis of the Phase II Randomized DEEPER Trial by JACCRO: m-FOLFOXIRI + Cetuximab vs. m-FOLFOXIRI + Bevacizumab as Initial Treatment for Unresectable RAS & BRAF Wild-Type mCRC

FEATURING Yu Sunakawa
  • 309 views
  • January 20, 2023
  • 3